What the trials designed in this cell actually settle, and where practice is still reasoning from mechanism.
1 · Why this group is under-served by both the hormone receptor-positive and HER2-positive trials
Hormone receptor status divides HER2-positive metastatic disease into two groups of comparable size. Only one of them has a trial literature of its own, and it is not this one. This group is studied almost entirely as a subgroup of trials designed for a neighbouring question.
The exclusion runs in both directions. The hormone receptor-positive trials that built modern endocrine practice took HER2 positivity as an exclusion criterion. The HER2-positive trials enrolled this group and stratified for it. They were not powered within it. What sits between the two literatures is the largest single cell in metastatic breast cancer without a dedicated evidence base.
The consequence has a specific shape. Almost every headline figure a reader knows for this group comes from a subgroup of a trial that was asking something else. The standard for what a subgroup can support is set in Clinical trials and evidence interpretation, and applying it here is uncomfortable. Much of what is practised in this group rests on analyses that were neither powered nor prespecified as primary.
The biology says this should matter rather than being a bookkeeping complaint. Reciprocal signalling between the oestrogen receptor and the HER2 axis, described in Estrogen receptor signaling and endocrine resistance and HER family signaling, makes each pathway an escape route from blockade of the other. Blocking HER2 restores oestrogen receptor signalling. Blocking the receptor pushes growth signalling back through HER2. A tumour carrying both has a route out that a tumour carrying one does not.
That is the argument for treating both axes. It is also the argument for expecting this group to behave differently from the hormone receptor-negative half of every HER2 trial it was enrolled in. The trials were not built to test either claim.
Before any of that, be clear about what the label measures. Triple-positive is an intersection of two assays read against two conventions rather than a biological class. Oestrogen receptor positivity is a stain scored against a low threshold, and the tumours sitting just above it do not behave like the strongly positive ones ER and PR testing, thresholds, and the ER-low category. HER2 positivity is a separate stain with a separate scoring rule and its own spatial variation HER2 heterogeneity and hormone receptor signaling in triple-positive disease. A patient whose tumour is weakly positive on both assays has been placed in this category by two conventions acting together. The endocrine arm of the strategy is the one that convention puts most at risk.
Each section below opens with the question its trials were built to answer, taken from the [Chapter Stories](stories.html) map, and closes with a table filtered on that same question. The story says what was being looked for and what the design cannot settle. The table says what else is in the cell. The prose argues the decision.
2 · Endocrine maintenance after induction
Advanced disease · HR+/HER2+ · any
The luminal half of a HER2-driven cancer
Does a tumour that is both hormone receptor-positive and HER2-positive need both pathways blocked?
Rationale
The two pathways hold each other up. Blocking HER2 restores oestrogen receptor signalling. Blocking the receptor pushes growth signalling back through HER2. Either drug given alone therefore leaves an escape route open.
Experiment
Chemotherapy-free randomisations in this cell built the case in two steps. TAnDEM and EGF30008 added a HER2-directed drug to an aromatase inhibitor. PERTAIN and ALTERNATIVE added a second HER2-directed drug to that pair. EGF30008 enrolled hormone receptor-positive patients regardless of HER2 status and made the HER2-positive group its prespecified primary analysis. ALTERNATIVE asked its question in patients who had already had trastuzumab and endocrine therapy.
Finding
Each addition delayed progression against the regimen it was added to. In the trial that enrolled both HER2 groups the gain appeared only where HER2 was amplified. That is an internal control the single-subtype trials do not have.
Limitation
Every control arm here is a regimen no clinic would now offer, either endocrine therapy alone or a single antibody with endocrine therapy. ALTERNATIVE enrolled only patients for whom chemotherapy was not intended, which selects on a clinician's judgement rather than on anything measured. Most of TAnDEM's endocrine-only arm crossed to trastuzumab on progression, leaving its survival comparison unable to settle anything. PERTAIN's own overall survival came out no different between its arms. None of these trials set the chemotherapy-free combination against dual blockade with a taxane.
Next question
If endocrine therapy with HER2 blockade controls this disease at all, can it stand in for chemotherapy rather than be arranged around it?
TAnDEMEGF30008PERTAINALTERNATIVE
Chemotherapy-free and maintenance endocrine trials designed in this population.
Every control arm here is a regimen a clinic would no longer offer.
hormone receptor-positive HER2-positive metastatic disease without progression after four to eight cycles of induction chemotherapy with HER2-targeted therapy
palbociclib added to maintenance HER2-targeted and endocrine therapy vs maintenance HER2-targeted and endocrine therapy alone
median progression-free survival 44.3 vs 29.1 months, HR 0.75, 95% CI 0.59 to 0.96, P = 0.02
Patients with HER2-positive advanced breast cancer who had received two to four prior anti-HER2-based regimens; the randomised cohort C additionally required hormone receptor-positive disease and a PAM50 luminal A or B subtype.
In cohort C, palbociclib, trastuzumab and endocrine therapy versus trastuzumab-based treatment of physician's choice, randomised 1:1, with patients allocated to the physician's choice arm eligible for re-randomisation on progression if they still met the inclusion criteria; the earlier cohorts gave palbociclib plus trastuzumab in estrogen receptor-negative disease (cohort A) and in estrogen receptor-positive disease without or with letrozole (cohorts B1 and B2).
In cohort C the triplet was associated with significantly better progression-free survival than trastuzumab-based treatment of physician's choice, stratified hazard ratio 0.52 (95% CI, 0.29 to 0.95; two-sided P = 0.03). Progression-free survival rates after 24 months were 24.0% with the triplet and 4.3% with physician's choice.
Not reported. Neither the randomised cohort C publication nor the earlier single-arm cohort publication reports overall survival.
Patients with hormone receptor positive and HER2 positive metastatic breast cancer receiving first-line treatment.
Trastuzumab plus endocrine therapy versus trastuzumab plus chemotherapy.
Median progression-free survival was 19.2 months with trastuzumab plus endocrine therapy and 14.8 months with trastuzumab plus chemotherapy, hazard ratio 0.88, 95 percent CI 0.71 to 1.09, noninferiority p less than 0.0001.
Postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer after prior endocrine therapy and prior trastuzumab, for whom chemotherapy was not intended.
Lapatinib plus trastuzumab plus aromatase inhibitor vs trastuzumab plus aromatase inhibitor vs lapatinib plus aromatase inhibitor.
The risk of progression or death was 38% lower with lapatinib plus trastuzumab plus aromatase inhibitor than with trastuzumab plus aromatase inhibitor. The hazard ratio was 0.62 (95% CI 0.45 to 0.88; P = .0063).
Overall survival favoured lapatinib plus trastuzumab plus aromatase inhibitor. No overall survival figures are given in the abstract.
Postmenopausal women with hormone receptor-positive metastatic breast cancer receiving first-line therapy, enrolled regardless of HER2 status.
Letrozole plus lapatinib versus letrozole plus placebo.
In the 219 HER2-positive patients, median progression-free survival was 8.2 months with lapatinib plus letrozole and 3.0 months with letrozole plus placebo, hazard ratio 0.71 (95% CI 0.53 to 0.96, P=.019). The 952 centrally confirmed HER2-negative patients had no improvement.
Postmenopausal women with HER2 positive and hormone receptor positive metastatic breast cancer.
Anastrozole plus trastuzumab versus anastrozole alone, given until progression.
Median progression-free survival was 4.8 months with trastuzumab plus anastrozole and 2.4 months with anastrozole alone, hazard ratio 0.63, 95 percent CI 0.47 to 0.84, p=0.0016.
Overall survival showed no statistically significant difference between the arms, in the overall and centrally confirmed hormone receptor positive populations, with 70 percent of the anastrozole alone arm crossing over to trastuzumab.
The pattern in practice is induction chemotherapy with dual HER2 blockade until best response, then chemotherapy stops and endocrine therapy joins the continuing antibodies. Adoption is close to universal. What sits under it is a ladder of superseded control arms rather than a test of the pattern itself.
Read the control arms in that table before the results. Every trial in it that added a drug to an existing regimen found the same thing. Each randomised addition delayed progression against the regimen it was added to. That is a finding about the strategy rather than about any drug. Adding an antibody to an aromatase inhibitor beat the inhibitor alone. Adding a second HER2-directed drug to that pair beat the pair. Adding a CDK4/6 inhibitor to antibody and endocrine maintenance beat the maintenance. No entry compares any two of those regimens with each other.
The table therefore looks like a disagreement about how much HER2 blockade an endocrine backbone needs. It is not. TAnDEM and EGF30008 were designed when the alternative on offer was endocrine therapy alone. PERTAIN and ALTERNATIVE were designed when it was one antibody with an aromatase inhibitor. PATINA was designed when it was HER2-directed treatment with endocrine therapy, continued after chemotherapy stopped. Each control arm is the previous experimental arm. The divergence down the rows is chronological, and reading it as a comparison between drugs is the commonest error made with this table.
Two entries sit off that ladder. ALTERNATIVE is the only one that required prior trastuzumab with chemotherapy, given as neoadjuvant, adjuvant or first-line treatment, so it asks what to do after trastuzumab rather than before it5. It also enrolled only patients for whom chemotherapy was not intended, which selects on a clinician's judgement rather than on anything measured. Its primary report gave a median progression-free survival of 11 months with the triplet against 5.7 months with trastuzumab and an aromatase inhibitor, a hazard ratio of 0.628. Lapatinib with an aromatase inhibitor also beat that control, at 0.71. The updated analysis no longer separated those two arms, at 0.855. SYSUCC-002 runs the ladder sideways instead of up, because it swapped the antibody's partner rather than adding to it, and because it was powered for noninferiority rather than superiority4. It is argued in Chemotherapy omission and the evidence that supports it.
EGF30008 is the only entry whose population was not defined by HER2 status at all. That makes its centrally confirmed HER2-negative stratum an internal negative control, which no single-subtype trial in the table can offer Subgroup analyses from the major trials and what they can support.
Overall survival is the column this table fills worst, and the reasons are design rather than effect. Most of the endocrine-only arm in TAnDEM crossed to trastuzumab on progression, which leaves its survival comparison unable to settle anything7. PERTAIN reported survival and found its arms no different, in a trial whose progression endpoint had separated them9,3. In eLEcTRA, first-line letrozole with trastuzumab gave a clinical benefit rate of 65% against 39% with letrozole alone. Median time to progression was 14.1 against 3.3 months, but the difference did not reach significance, with a hazard ratio of 0.67 and P equal to 0.2310. ALTERNATIVE reported a direction without figures. SYSUCC-002 reported overall survival as a secondary endpoint and found no significant difference between its arms4. PATINA has not reported survival at all. A reader who wants to know what any of this buys in time alive is not served by the table, and on these designs will not be.
The decision a clinic actually makes is narrower than anything randomised here. It is whether to attach endocrine therapy to the antibodies at the point chemotherapy stops. No trial in the table randomised that. PATINA comes closest, because its control arm is the maintenance pattern itself and is the only modern estimate of what that pattern delivers1. It did not test the pattern. It assumed it, in both arms.
So endocrine maintenance rests on mechanism. Oestrogen receptor signalling is upregulated as an adaptive survival mechanism in HER2-positive tumours under anti-HER2 therapy11. If an unblocked receptor is an escape route from HER2 blockade, leaving it unblocked through a phase measured in years leaves the route open. That is a reasonable inference from Estrogen receptor signaling and endocrine resistance, and it should be labelled as an inference rather than reported as evidence. Real-world series support the maintenance itself rather than any particular addition to it12.
The choice of agent inside maintenance has less behind it still. Every trial in this cell that fixed its endocrine partner fixed it as an aromatase inhibitor. None compared one endocrine class against another in the presence of HER2 blockade. TAnDEM, EGF30008 and ALTERNATIVE were restricted to postmenopausal women by protocol. SYSUCC-002 is the only entry that allowed ovarian suppression, and it also left the endocrine agent to the investigator, so it cannot separate the agent from the choice. Extrapolating to ovarian suppression with an aromatase inhibitor is reasonable. It is still extrapolation, which is worth saying to a young patient who asks what the evidence is.
3 · CDK4/6 inhibition with HER2 blockade
The luminal half of a HER2-driven cancer, continued
After HER2-directed regimens have failed, does a CDK4/6 inhibitor with trastuzumab and endocrine therapy beat returning to chemotherapy?
Rationale
Cyclin D1 and CDK4/6 sit downstream of both the oestrogen receptor and HER2, which makes them the node where the two pathways converge. Escape from HER2 blockade runs through that node. Blocking it would also put a chemotherapy-free option into a line where chemotherapy is the default.
Experiment
monarcHER randomised pretreated triple-positive patients three ways: abemaciclib with trastuzumab and fulvestrant, abemaciclib with trastuzumab, and physician's choice chemotherapy with trastuzumab. The two-drug arm carries the same CDK4/6 inhibitor without the endocrine partner, which is what isolates the endocrine contribution. SOLTI-1303 PATRICIA later ran the same three-drug idea against trastuzumab-based physician's choice in a population with a lower entry bar. Its randomised cohort needed only one prior line for advanced disease, or early relapse after adjuvant HER2-directed therapy.
Finding
Only the arm carrying the endocrine partner improved on chemotherapy for time to progression. The same CDK4/6 inhibitor without it was no better than chemotherapy. Overall survival ran in the same direction on a comparison that carried no alpha of its own.
Limitation
This was a screening phase II. Its progression-free survival result was declared against a significance threshold much looser than a phase III would use, which makes it a signal to be confirmed rather than a confirmation. Its chemotherapy control predates DESTINY-Breast03, which moved the conjugate into the line ahead of this one and changed what a patient now arrives here having already had. Entry turned on receptor positivity by immunohistochemistry, with no requirement that the tumour behave as a luminal one.
Next question
If the endocrine partner is what makes the combination work, does the tumour have to be luminal by more than a receptor stain?
monarcHERDESTINY-Breast03SOLTI-1303 PATRICIA
Does the benefit hold only in tumours that are luminal by intrinsic subtype, rather than in every tumour that stains receptor-positive?
Rationale
Receptor positivity is a protein stain read against a scoring threshold. Intrinsic subtyping reads the transcriptional programme instead. A substantial share of receptor-positive, HER2-positive tumours classify as HER2-enriched rather than luminal. If the luminal programme is what the endocrine drug and the CDK4/6 inhibitor exploit, then the stain is only a proxy for the thing being selected on.
Experiment
SOLTI-1303 PATRICIA ran single-arm cohorts of palbociclib with trastuzumab, split by oestrogen receptor status and given with or without letrozole. On a secondary analysis, luminal tumours ran longer before progressing than non-luminal ones. The trial then closed those cohorts and opened a randomised one restricted to PAM50 luminal disease, comparing palbociclib with trastuzumab and endocrine therapy against trastuzumab-based treatment of physician's choice.
Finding
In the subtype-restricted randomised cohort the triplet delayed progression against physician's choice. A tail of patients on the triplet was still free of progression long after almost everyone on physician's choice had progressed.
Limitation
The subtype rule was derived in this study's own earlier cohorts and then tested in a cohort built around it. No randomised non-luminal comparison exists to show that the rule excludes anyone correctly. The control arm was trastuzumab-based treatment of the investigator's choosing, which put a conjugate, chemotherapy and endocrine therapy into a single comparator. Patients allocated to that arm could be randomised again on progression, leaving more randomised assignments than distinct participants. The cohort reports no overall survival.
Next question
If subtype picks out who benefits after HER2-directed lines have failed, does the same selection apply earlier, where a CDK4/6 inhibitor is given to everyone whose disease has responded to induction?
SOLTI-1303 PATRICIAmonarcHERPATINA
Is the right moment for a CDK4/6 inhibitor the maintenance phase after induction, rather than a later line?
Rationale
First-line treatment in this cell ends in a long maintenance phase on HER2-directed and endocrine therapy, with the disease quiet and the residual burden small. Holding proliferation down is exactly what a CDK4/6 inhibitor does. monarcHER and SOLTI-1303 PATRICIA handed the class tumours that had already escaped HER2-directed therapy, in monarcHER at least twice, and had time to find other routes.
Experiment
PATINA randomised patients whose disease had not progressed after induction chemotherapy with HER2-directed treatment. One arm added palbociclib to maintenance HER2-directed and endocrine therapy. The other continued that maintenance alone. No subtype or biomarker selection was applied.
Finding
Adding the CDK4/6 inhibitor lengthened the maintenance phase against the same maintenance without it, in an unselected receptor-positive population. It also brought the neutropenia the class brings into a phase in which patients feel well.
Limitation
Randomisation came after induction, selecting a population whose disease did not progress on chemotherapy with HER2 blockade. The trial says what palbociclib adds to a patient who is already responding, not what it adds to everyone who starts first line. Its overall survival is not yet reported. Its induction belongs to the era CLEOPATRA defined, and DESTINY-Breast09 has since moved first-line treatment to a conjugate with dual blockade. The maintenance phase PATINA improved is therefore not quite the one a clinic will be managing.
Next question
If first-line induction becomes an antibody-drug conjugate with dual blockade, is there still a maintenance phase to put an endocrine and CDK4/6 backbone into, and would the subtype assay be needed to find the patients for it?
hormone receptor-positive HER2-positive metastatic disease without progression after four to eight cycles of induction chemotherapy with HER2-targeted therapy
palbociclib added to maintenance HER2-targeted and endocrine therapy vs maintenance HER2-targeted and endocrine therapy alone
investigator-assessed progression-free survival
median progression-free survival 44.3 vs 29.1 months, HR 0.75, 95% CI 0.59 to 0.96, P = 0.02
Patients with HER2-positive advanced breast cancer who had received two to four prior anti-HER2-based regimens; the randomised cohort C additionally required hormone receptor-positive disease and a PAM50 luminal A or B subtype.
In cohort C, palbociclib, trastuzumab and endocrine therapy versus trastuzumab-based treatment of physician's choice, randomised 1:1, with patients allocated to the physician's choice arm eligible for re-randomisation on progression if they still met the inclusion criteria; the earlier cohorts gave palbociclib plus trastuzumab in estrogen receptor-negative disease (cohort A) and in estrogen receptor-positive disease without or with letrozole (cohorts B1 and B2).
Investigator-assessed progression-free survival by RECIST version 1.1 in cohort C; progression-free survival rate at 6 months in cohorts A, B1 and B2.
In cohort C the triplet was associated with significantly better progression-free survival than trastuzumab-based treatment of physician's choice, stratified hazard ratio 0.52 (95% CI, 0.29 to 0.95; two-sided P = 0.03). Progression-free survival rates after 24 months were 24.0% with the triplet and 4.3% with physician's choice.
Not reported. Neither the randomised cohort C publication nor the earlier single-arm cohort publication reports overall survival.
Women with hormone receptor-positive, HER2-positive advanced breast cancer who had received at least two prior HER2-targeted therapies for advanced disease.
Abemaciclib plus trastuzumab plus fulvestrant, or abemaciclib plus trastuzumab, versus physician's choice chemotherapy plus trastuzumab
Investigator-assessed progression-free survival in the intention-to-treat population
Median progression-free survival was 8.3 months with abemaciclib, trastuzumab, and fulvestrant versus 5.7 months with chemotherapy plus trastuzumab, hazard ratio 0.67, p=0.051 against a prespecified two-sided alpha of 0.2. Abemaciclib plus trastuzumab alone gave 5.7 months, hazard ratio 0.94, p=0.77.
Median overall survival was 31.1 months with abemaciclib, trastuzumab, and fulvestrant, 29.2 months with abemaciclib plus trastuzumab, and 20.7 months with chemotherapy plus trastuzumab. The triplet versus chemotherapy hazard ratio was 0.71, nominal p=0.086.
Cyclin D1 and CDK4/6 sit downstream of both the oestrogen receptor and the HER2 axis, which is the convergence described in Cell cycle regulation. Blocking a convergence point is a different strategy from blocking the two inputs above it. It predicts activity where blockade of either input alone has failed.
All three trials in that table support the prediction. Two of them sit after HER2-directed therapy has failed, monarcHER after at least two lines, and the third sits in first-line maintenance. They are not a series. The line, the selection rule and the control arm change together between them, so nothing in the table compares one CDK4/6 inhibitor with another.
monarcHER isolates the endocrine contribution by design rather than by subgroup13. Its second arm gave the same CDK4/6 inhibitor with trastuzumab and no endocrine partner. Only the arm carrying the endocrine partner improved on chemotherapy. That internal comparison is worth more than the headline, because it says which component is doing the work.
It is a screening study and should be read as one. Its progression-free survival result was declared against a prespecified two-sided alpha of 0.2, a threshold for deciding what to test next rather than what to do13. The distinction is the subject of Statistical and clinical significance are different claims. Its survival comparison carried no alpha of its own14. Its chemotherapy control predates the move of a conjugate into second line, so its patients arrived with less behind them than a patient arriving there today.
SOLTI-1303 PATRICIA pushes the selection from a receptor stain to a transcriptional class2. That is a measurement argument rather than a biological one. A receptor stain read against a scoring threshold and a PAM50 call on the same tumour disagree often enough that neither stands in for the other. The subtype rule was derived in the study's own earlier single-arm cohorts, then tested in a randomised cohort built around it15. That is hypothesis generation and confirmation inside one protocol. Its randomised assignments include seven re-randomisations of patients already allocated once, so there are fewer participants than the number in the table. No non-luminal randomised cohort was ever run, so nothing shows the rule excludes anyone correctly.
PATINA asked the question at the other end of the course, and is the only phase III of the three1. It randomised patients whose disease had not progressed after induction, with no biomarker selection at all. Its population is selected by response rather than by assay, and its control arm is the maintenance a clinic already gives. That is what makes it the trial the decision rests on. Median progression-free survival was 44.3 months with palbociclib against 29.1 months without it1. It says what a CDK4/6 inhibitor adds to a patient who is already doing well. It does not say what it adds to everyone who starts first-line treatment.
The price belongs in the same sentence as that gain, because of where it is paid. Grade 3 adverse events occurred in 79.7% of patients on palbociclib against 30.6% without it, predominantly neutropenia1. Those events are incurred in maintenance, in patients who are well and who have already finished their chemotherapy. Overall survival has not been reported, so the trade on offer is a progression endpoint against a measured toxicity rate.
Two things the table cannot settle. None of the three carries a survival result that can be leaned on. That gap matters most for PATINA, which proposes years of an added drug in a phase when patients feel well and neutropenia is felt. Nobody has randomised the selection question either. SOLTI-1303 PATRICIA selected on subtype and PATINA selected on nothing, at different points in the disease course, so the two cannot be set against each other.
4 · Chemotherapy omission and the evidence that supports it
The luminal half of a HER2-driven cancer, continued
Can endocrine therapy stand in for chemotherapy alongside HER2-directed treatment?
Rationale
First-line treatment pairs HER2 blockade with a taxane, on the record CLEOPATRA built. The taxane is the part the patient pays for. If the tumour depends on oestrogen as much as on HER2, an endocrine agent is the cheaper partner for the antibody.
Experiment
SYSUCC-002 randomised untreated metastatic patients to trastuzumab with endocrine therapy or trastuzumab with chemotherapy. It was powered to show that the endocrine partner was not worse than the cytotoxic one by more than a prespecified margin on progression-free survival. PERTAIN puts a version of the same question informally, because induction chemotherapy in it was left to investigator discretion.
Finding
The endocrine partner met the noninferiority margin against chemotherapy for time to progression, at lower toxicity than the chemotherapy arm carried. In PERTAIN, among the patients who had no induction chemotherapy at all, adding the second antibody to endocrine therapy separated the arms at least as far as it did in the trial as a whole.
Limitation
The SYSUCC-002 control was a single antibody with chemotherapy rather than the dual blockade with a taxane that CLEOPATRA had already made standard. Noninferiority was therefore shown against a comparator its own era had improved on. Its margin was set on progression-free survival. Its overall survival, a secondary endpoint, did not differ significantly between the arms, but the trial was powered on progression-free survival rather than on survival. The PERTAIN comparison is not randomised at all, because induction was an investigator's decision. Its chemotherapy-free group is a group judged not to need chemotherapy.
Next question
If the endocrine partner can carry a whole line, can it also carry one after HER2-directed treatment has failed, where chemotherapy is the default?
SYSUCC-002PERTAINCLEOPATRA
The live de-escalation question here is whether chemotherapy is needed at all in a patient with low-burden, indolent disease and two targetable pathways. The argument for omission is that such a patient has a trajectory measured in years. Chemotherapy contributes toxicity to a regimen whose activity comes from targeted agents.
SYSUCC-002 is the only randomised test of that idea, and its shape decides what it can support4. It compared an antibody with endocrine therapy against the same antibody with chemotherapy, powered for noninferiority on progression-free survival. Its comparator was a single antibody with chemotherapy rather than the dual blockade with a taxane that CLEOPATRA had already made standard. Noninferiority was therefore demonstrated against a regimen its own era had improved on. Its overall survival, a secondary endpoint, did not differ significantly between the arms, but the trial was powered on progression-free survival rather than on survival.
The margin discipline in Designing de-escalation trials and the non-inferiority margin problem is the reason to be careful with the reading. A trial showing no significant difference between a chemotherapy-containing and a chemotherapy-free regimen does not establish equivalence unless it was powered against a prespecified margin. A margin set against a superseded comparator does not transfer to the comparator it has been superseded by.
PERTAIN puts a version of the same question informally, because induction chemotherapy in it was left to investigator discretion3. Its chemotherapy-free group is a group a clinician judged did not need chemotherapy. That is not a randomised comparison and it cannot be converted into one. Retrospective and real-world series carry the same defect in a larger form, because the patients in whom clinicians omit chemotherapy are the patients with indolent disease.
In practice
Before omitting chemotherapy outside a trial, state what you would accept as the cost. A patient with a decade of expected survival and low disease burden is a different proposition from one with visceral crisis, and the second is not a de-escalation candidate whatever the receptor profile.
Say whether you are omitting chemotherapy or deferring it. Deferral keeps an option and is the easier decision to revisit at the first scan.
Record the reason in the notes. The next clinician needs to know whether the patient declined chemotherapy, could not have it, or was judged not to need it.
5 · Conjugates in triple-positive disease
Randomised conjugate trials that enrolled this group.
Each was designed for HER2-positive disease as a whole, and none selected on the hormone receptor.
HER2-positive advanced or metastatic disease with no prior chemotherapy or HER2-directed therapy for metastatic disease; randomised 1:1:1, and 770 patients in the two unblinded groups are reported at this prespecified interim analysis, 383 given the conjugate with pertuzumab and 387 given the taxane triplet, with the third group still blinded
trastuzumab deruxtecan plus pertuzumab vs taxane, trastuzumab and pertuzumab
median progression-free survival 40.7 vs 26.9 months, HR 0.56, 95% CI 0.44 to 0.71
HER2-positive metastatic disease previously treated with trastuzumab and a taxane, all conjugate-naive
Trastuzumab deruxtecan versus trastuzumab emtansine, randomised 1:1 in a multicentre open-label trial.
progression-free survival at 12 months 75.8% against 34.1% with trastuzumab emtansine, hazard ratio 0.28. The updated analysis gave medians of 28.8 months against 6.8
median 52.6 months against 42.7 months, hazard ratio 0.73, in the long-term analysis
Centrally confirmed HER2-positive advanced breast cancer with no prior chemotherapy for advanced disease; prior endocrine therapy for advanced disease was allowed.
T-DM1 alone or T-DM1 plus pertuzumab versus trastuzumab plus a taxane
Median progression-free survival was 13.7 months with trastuzumab plus taxane, 14.1 months with T-DM1, and 15.2 months with T-DM1 plus pertuzumab. Both T-DM1 arms were noninferior to trastuzumab plus taxane. Neither was superior.
Not yet reported. The primary publication gives no overall survival result.
HER2+ advanced disease after trastuzumab and a taxane
trastuzumab emtansine vs lapatinib plus capecitabine
median PFS 9.6 vs 6.4 months, HR 0.65 (0.55-0.77)
30.9 vs 25.1 months, HR 0.68 (0.55-0.85)
Conjugates do not care about the oestrogen receptor. A HER2-directed conjugate delivers payload to a HER2-expressing cell whether or not that cell also expresses the oestrogen receptor. There is no mechanistic reason to expect reduced activity in this group. In the trials whose hormone receptor-positive stratum has been reported, that stratum tracked the trial it sat inside20,19,17.
What differs between the rows is not the receptor. EMILIA set a conjugate against lapatinib with capecitabine. TH3RESA set the same conjugate against treatment of physician's choice after two or more HER2-directed regimens. DESTINY-Breast03 set a newer conjugate against the older one. DESTINY-Breast09 set a conjugate with pertuzumab against a taxane with dual blockade, before anything else. MARIANNE set the older conjugate, alone or with pertuzumab, against trastuzumab with a taxane at the same position, and it was non-inferior without being superior18. Five control arms and three positions in the sequence, because two of them enter after trastuzumab and a taxane. A reader comparing progression-free survival down the column is comparing comparators.
TH3RESA is the row whose control arm still resembles a real decision, because physician's choice is what a heavily pretreated patient is otherwise offered19. Its survival comparison did not cross its own stopping boundary at the interim analysis, which is a statement about the analysis plan rather than about the drug. Its final survival analysis is a separate report and is not the figure the table carries21. EMILIA matters now mainly as the trial that established the class in second line, after trastuzumab and a taxane, against a comparator nobody offers20,22.
The decision rests on DESTINY-Breast03, because it is the only randomised comparison against the conjugate a clinic would otherwise reach for17,23. Nothing in its hormone receptor-positive stratum argues for handling this group differently from the rest of the subtype.
What the table cannot show is the endocrine question. No conjugate trial carries an endocrine-containing arm. None asked whether endocrine therapy should run alongside a conjugate, be held through it, or resume after it. That is the one thing distinguishing this group from the rest of HER2-positive disease, and it is the comparison nobody randomised. The conjugate therefore competes for position against endocrine therapy as well as against other HER2-directed agents, on no evidence at all.
DESTINY-Breast09 sharpens that problem rather than solving it16. Its third group is still blinded and its overall survival is not yet reported, so its row is an interim view of a trial that has not finished speaking. If first-line induction becomes a conjugate with dual blockade, the maintenance phase PATINA improved is not quite the phase a clinic will be managing. A trial that randomised after chemotherapy-based induction has been overtaken at its starting point.
The ordering decision that follows has no trial behind it and is made weekly. A patient with slow, low-burden disease and an intact endocrine axis can often be held on endocrine therapy with HER2 blockade while the conjugate is kept in reserve. A patient with rapid visceral progression cannot, and the conjugate is the agent with the response rate to match the tempo. That is a judgement about disease behaviour rather than about receptor status, and When the target changes, and when to stop blocking it sets out how to make it.
Interplay
A tumour scored positive for both receptors on one core may contain regions expressing one and not the other. That is the discordance documented in Receptor discordance and conversion and the spatial HER2 variation in HER2 heterogeneity. Treating both axes at once is therefore partly a hedge against a sampling problem rather than only a hedge against resistance. It also means a failure attributed here to biology may be a failure of the block that was stained, which is the ceiling argued in Where heterogeneity sets a ceiling on precision medicine.
6 · Subgroup analyses from the major trials and what they can support
Most of what is known about this group comes from hormone receptor-positive subgroups of the HER2-positive registration trials. Those subgroups are informative. They have three limits that should be stated whenever they are used.
They were not powered. A subgroup holding roughly half a trial holds roughly half its events, with a correspondingly wider confidence interval. An apparently smaller effect in one subgroup is frequently compatible with the overall effect of the trial.
They are prone to the interaction fallacy. A treatment effect that reaches significance in one subgroup and not in the other is not evidence of a differential effect. Establishing that requires a test of interaction, which is less often reported and less often significant than the subgroup comparison it would qualify.
EGF30008 is the exception worth naming, because it was not a subgroup analysis at all6. It enrolled hormone receptor-positive patients regardless of HER2 status and made the HER2-positive group its prespecified primary analysis. The benefit appeared where HER2 was amplified and not in the centrally confirmed HER2-negative population. That is an internal control no single-subtype trial can offer, and it is the strongest evidence in this chapter that the target is the target. It is also a measurement claim as much as a biological one, because the negative stratum was defined by central confirmation rather than by the local report.
One consistent observation across trials is prognostic rather than predictive. Hormone receptor-positive HER2-positive disease follows a more indolent trajectory and a later relapse pattern than the hormone receptor-negative half of the same subtype. That describes the natural history. It should not be converted into a claim that treatment works less well, which is a different proposition needing a different analysis Statistical and clinical significance are different claims.
7 · Unresolved questions and what reads out next
The questions this group needs answered are questions no current trial is powered for.
Whether endocrine therapy should run concurrently with induction rather than start at maintenance. Mechanism argues for concurrent, because an unblocked receptor is an open escape route from the first cycle onwards. No trial has compared the two schedules.
Whether chemotherapy can be omitted in selected patients. This needs a de-escalation trial with a prespecified margin, in this population, against a modern comparator. It does not exist, and SYSUCC-002 is not a substitute for it.
Whether the selection should be a stain or a transcriptional class. SOLTI-1303 PATRICIA argues for the class and derived its rule in its own earlier cohorts. PATINA improved outcomes with no selection at all. The two sit at different points in the disease course, so neither tests the other's rule.
Whether there is still a maintenance phase to put a CDK4/6 inhibitor into. That depends on what first-line treatment becomes after DESTINY-Breast09, which is a question about induction rather than about maintenance.
Whether this group should be enrolled separately rather than stratified. That is a trial design question and it is the one that would fix the others. A population that is half of a common subtype and is studied only as a subgroup will keep generating practice that rests on subgroups.
References
All 23 references
Metzger O, Mandrekar S, Goel S, et al. Palbociclib for hormone-receptor-positive, HER2-positive advanced breast cancer. N Engl J Med 2026 394:451-462. PMID 41604639
Ciruelos E, et al. Palbociclib, trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer (SOLTI-1303 PATRICIA cohort C). Clin Cancer Res 2026. PMID 41335375
Arpino G, et al. Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis. Clin Cancer Res 2023 29:1468-1476. PMID 36716289
Hua X, et al. Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002). Clin Cancer Res 2022 28:637-645. PMID 34810217
Johnston SRD, et al. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE. J Clin Oncol 2020 39:79-89. PMID 32822287
Johnston S, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009 27:5538-46. PMID 19786658
Kaufman B, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009 27:5529-37. PMID 19786670
Johnston SRD, Hegg R, Im SA, et al. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE. J Clin Oncol 2018 36:741-748. PMID 29244528
Rimawi M, et al. First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. J Clin Oncol 2018 36:2826-2835. PMID 30106636
Huober J, Fasching PA, Barsoum M, et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. Breast 2012 21:27-33. PMID 21862331
Giuliano M, et al. Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy. Clin Cancer Res 2015. PMID 26015514
Carausu M, et al. Association of endocrine therapy for HR+/ERBB2+ metastatic breast cancer with survival outcomes (ESME real-world cohort). JAMA Netw Open 2022. PMID 36520434
Tolaney SM, et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncol 2020 21:763-775. PMID 32353342
Tolaney SM, et al. Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients. Clin Cancer Res 2024 30:39-49. PMID 37906649
Ciruelos E, Villagrasa P, Pascual T, et al. Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. Clin Cancer Res 2020 26:5820-5829. PMID 32938620
Tolaney SM, Jiang Z, Zhang Q, et al. Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer. N Engl J Med 2026 394:551-562. PMID 41160818
Cortes J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 2022 386:1143-1154. PMID 35320644
Perez EA, et al. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. J Clin Oncol 2016 35:141-148. PMID 28056202
Krop IE, Kim SB, Gonzalez-Martin A, et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014 15:689-699. PMID 24793816
Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012 367:1783-1791. PMID 23020162
Krop IE, et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol 2017 18:743-754. PMID 28526538
Diéras V, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 2017 18:732-742. PMID 28526536
Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 2023 401:105-117. PMID 36495879